Study Overview

This Phase 2 trial was sponsored by the Mayo Clinic, initiated in May 2018 and completed in 202?. The study enrolled prostate cancer patients with high‑risk features following radical prostatectomy and evaluated the efficacy of hypofractionated radiation therapy. The trial is listed as Completed, and data release is anticipated.

What Is Hypofractionated Radiation Therapy?

Hypofractionated radiation therapy delivers a higher dose per fraction over a shorter overall treatment period compared with conventional regimens. The escalated dose can more effectively eradicate tumor cells and reduce the number of treatment sessions, potentially lowering toxicity. However, the increased dose concentration also necessitates careful assessment of normal‑tissue injury risk.

Differences From Standard Therapy

Traditionally, adjuvant radiation after radical prostatectomy is delivered in conventional fractions of 1.8–2.0 Gy over 7–8 weeks for a total dose of 60–70 Gy. The hypofractionated approach administers the same total dose within 3–4 weeks, markedly improving patient convenience and offering potential cost savings. Moreover, the altered toxicity profile may expand therapeutic options.

Impact on Patients and Healthcare Systems

Shortening the treatment course can accelerate patients’ return to work and daily activities, thereby improving quality of life (QoL). For treatment centers, higher utilization efficiency of radiation equipment enables treatment of a larger patient volume. However, upfront costs for equipment upgrades and implementation of new protocols may represent an initial financial burden.

Future Development

If the Phase 2 results are favorable, expansion into a multicenter Phase 3 trial is likely, providing a critical foundation for regulatory approval and broader reimbursement. Commercial manufacturers of radiation therapy equipment and providers of radiation oncology services should monitor this trend closely.